Interim data from an ongoing phase 2 trial of IMO-2125+ipilumumab in this indication could be announced at the upcoming annual meeting of the European Society for Medical Oncology, ESMO in September. Data on objective response rate from the trial is expected in Q1, 2018. Phase 2 data of another molecule IMO-8400 in dermatomyositis is also expected in the first half of 2018. Median analyst price target is $6 (2.5 times upside potential). Prominent institutions like Baker Brothers and Broadfin hold the stock.